Montero M C, Valdivia M L, Carvajal E, Montaño A, Buenestado C, Lluch A, Atienza M
Servicio de Farmacia, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Pharm World Sci. 1994 Aug 5;16(4):187-92. doi: 10.1007/BF01872867.
This article describes the economic and social impact of neutropenia induced by myelotoxic chemotherapy in patients with cancer during the period 1 January-31 December 1991. Neutropenia is a life-threatening complication of chemotherapy in patients with cancer. The episodes of fever and infections originating from neutropenia require hospitalization of the patient until the granulocyte levels are restored. The calculation of the economic cost was based on the following parameters: length of stay in hospital, analytical tests performed on the patient, type and cost of drug therapy administered, blood transfusions performed, health assistance received, cost of isolation and absence from work. The overall economic cost of neutropenia in patients with cancer reached 329,775 pesetas ($2,893). Cost of the health-care staff was the largest budget item in relation to the total health resources estimated.
本文描述了1991年1月1日至12月31日期间癌症患者骨髓毒性化疗所致中性粒细胞减少症的经济和社会影响。中性粒细胞减少症是癌症患者化疗的一种危及生命的并发症。由中性粒细胞减少症引发的发热和感染发作需要患者住院，直到粒细胞水平恢复。经济成本的计算基于以下参数：住院时间、对患者进行的分析测试、所给予药物治疗的类型和成本、输血情况、获得的医疗援助、隔离成本以及旷工成本。癌症患者中性粒细胞减少症的总体经济成本达到329,775比塞塔（2,893美元）。与估计的总卫生资源相关，医护人员成本是最大的预算项目。
